Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) in connection with SBB establishing a new joint venture with Castlelake, LP (“Castlelake”).
Mandate

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (“SBB”) in connection with SBB establishing a new joint venture with Castlelake, LP (“Castlelake”).

May 28, 2024

SBB has agreed to enter into a joint venture, SBB Social Facilities AB, together with funds managed by global alternative investment manager Castlelake and supported by ATLAS SP Partners (together the “Lenders”). In connection with the establishment of the joint venture, cash proceeds are released through a loan agreement between SBB Social Facilities and the Lenders for approximately SEK 5.7 billion. Closing will occur as soon as all closing conditions have been fulfilled, which is expected to occur in June 2024.

Vinge’s team consisted primarily of Mikael Ståhl, Helena Göransson, Rikard Lindahl, Ulrich Ziche, William Kåge, Kamyar Najmi, Ida Redander and Rebecka Margolin.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025